Valneva to Partner with Instituto Butantan on Single-Shot Chikungunya Vaccine for Low- and Middle- Income Countries


Valneva SE, a specialty vaccine company, and Instituto Butantan, producer of immunobiologic products is preparing to start Phase 3 clinical studies of a single-shot chikungunya vaccine, VLA1553, in the United States later this year.

Content Information

Content Author: 
VALNEVA
Content Source: 
VALNEVA
Content Type: 
News